TG Therapeutics at Goldman Sachs Conference: Strategic Growth and Innovations

TG Therapeutics (TGTX) presented at the Goldman Sachs Healthcare Conference, reaffirming its focus on Breumvy for B cell diseases and its goal to lead in CD20 therapy market share. The company highlighted progress in formulary coverage and marketing efforts, including doubling its field force and expanding online presence, with full-year revenue guidance for Breumvy set at $560 million. TG Therapeutics is also developing new Breumvy formulations, such as a single-day dose and subcutaneous option, while exploring new indications like MG and investing in a CAR T program, alongside a share buyback program reflecting confidence in long-term growth.

Analysis

TG Therapeutics (TGTX) presented a robust outlook at the Goldman Sachs Healthcare Conference, centered on its commercial-stage B cell disease drug, Breumvy. The company reaffirmed its full-year 2025 revenue guidance for Breumvy at $560 million, driven by new patient starts and treatment persistence, with management expressing high conviction in achieving this target and a potential for upside. TGTX is aggressively pursuing market leadership in the CD20 therapy space, evidenced by achieving formulary parity with key competitors like Ocrevus and, in some instances, preferred status. Commercial execution includes a doubled field force since Breumvy's launch, which has demonstrably increased market penetration, and an expanding marketing strategy encompassing online platforms and connected TV, despite initially operating with a minimal marketing budget. The company is also focused on enhancing Breumvy's patient experience and competitive profile through initiatives like consolidating dosing to a single day with potential data by mid-next year and a label update by mid-2027, developing a 30-minute infusion, and advancing a subcutaneous formulation aimed at competing with at-home injections like Kesimpta, targeting a distinct and growing 35-40% segment of the market with bioavailability data anticipated later this year or next. Beyond Breumvy lifecycle management, TGTX is exploring new indications such as Myasthenia Gravis (MG), NMO, and CIDP, and investing in its CAR T program, signaling a strategy for sustained growth. The initiation of a share buyback program underscores management's confidence in long-term value creation and shareholder returns.

Key Decisions for Investors

• Investors should monitor Breumvy's sales trajectory against its $560 million guidance and market share gains within the competitive CD20 landscape, particularly focusing on new patient starts and persistence rates.
• Close attention should be paid to clinical development milestones and timelines for Breumvy's enhanced formulations, especially the subcutaneous version, given its potential to access a significant new market segment and compete with established at-home therapies.
• The ongoing share buyback program and strategic capital allocation towards pipeline expansion, including new indications for Breumvy and the CAR T program, are key factors for assessing long-term value creation and potential returns.